Align Technology Announces Third Quarter 2019 Financial Results
- Q3 revenues up 20.2% year-over-year to a record $607.3 million
- Q3 Invisalign volume up 20.7% year-over-year to 385.4 thousand cases
- Q3 scanner and services revenues up 16.5% year-over-year to $91.1 million
- Q3 Invisalign cases for teens and kids were up 31.5% year-over-year to 129.6 thousand cases
- Q3 net profit of $102.5 million and $1.28 diluted EPS
SAN JOSE, Calif., Oct. 23, 2019 (GLOBE NEWSWIRE) -- Align Technology, Inc. (Nasdaq: ALGN) today reported financial results for the third quarter ended September 30, 2019. Q3’19 Invisalign volume was 385.4 thousand cases, up 20.7% year-over-year. For the Americas and International regions, Q3’19 Invisalign volume was up 13.0% and 32.1% year-over-year, respectively. Q3’19 Invisalign volume for teenage patients was 129.6 thousand cases, up 31.5% year-over-year. Q3’19 total revenues were $607.3 million, up 20.2% year-over-year, and Q3’19 scanner and services revenues were $91.1 million, up 16.5% year-over-year.
Q3’19 operating income was $127.2 million or operating margin of 20.9%. Q3’19 net profit was $102.5 million, or $1.28 per diluted EPS. Q3’19 operating expenses included a $6.8 million benefit from the settlement of our Invisalign Store leases, which increased Q3’19 operating margin by approximately 1.1 points and benefited diluted EPS by $0.06. This compares to Q2’19 operating income of $176.5 million or operating margin of 29.4% and Q2’19 net profit of $147.1 million, or $1.83 per diluted EPS. Q2’19 operating expenses included a $51.0 million benefit from the ClearCorrect settlement with Straumann, which increased Q2’19 operating margin by approximately 8 points and benefited diluted EPS by $0.57.
Commenting on Align’s third quarter results, Align Technology President and CEO Joe Hogan said, “I’m pleased to report revenues, volume, and earnings above our third quarter outlook driven by better than expected volume across the Invisalign portfolio in Asia Pacific and Latin America, reflecting record highs for both regions and improving trends in the North American orthodontic channel. Notwithstanding EMEA summer seasonality, we saw continued adoption from teens and especially younger patients using Invisalign First across the board. Q3 Invisalign volumes were up 20.7% year-over-year driven by growth across the product portfolio, as well as expansion of our customer base, which increased by 6,000 new Invisalign doctors for a total of 63,000 active doctors worldwide. The iTero scanner and services business was up 16.5% year over year reflecting continue growth across each region, and down sequentially as expected coming off a record second quarter.”
| GAAP Summary Financial Comparisons | ||||||||||||
| Third Quarter Fiscal 2019 | ||||||||||||
| Q3’19 | Q2’19 | Q3’18 | Q/Q Change | Y/Y Change | ||||||||
| Invisalign Case Shipments1 | 385,360 | 377,145 | 319,345 | +2.2% | +20.7% | |||||||
| Net Revenues | $607.3M | $600.7M | $505.3M | +1.1% | +20.2% | |||||||
| Clear Aligner2 | $516.3M | $496.7M | $427.1M | +3.9% | +20.9% | |||||||
| Scanner & Services | $91.1M | $104.0M | $78.2M | (12.4)% | +16.5% | |||||||
| Net Profit3 | $102.5M | $147.1M | $100.9M | (30.3)% | +1.6% | |||||||
| Diluted EPS3 | $1.28 | $1.83 | $1.24 | $(0.55) | +$0.04 | |||||||
| Note: Changes and percentages are based on actual values and may affect totals due to rounding | ||||||||||||
| 1 Invisalign shipment figures do not include SmileDirectClub aligners | ||||||||||||
| 2 Clear aligner revenue includes revenues from Invisalign clear aligners and SmileDirectClub aligners | ||||||||||||
| 3 Q2’19 results include a $51.0 million gain from Straumann litigation settlement | ||||||||||||
As of September 30, 2019, Align had $782.4 million in cash, cash equivalents and marketable securities compared to $765.9 million as of June 30, 2019. In July 2019, we entered into an accelerated stock repurchase agreement (“ASR”) to repurchase $200.0 million of our common stock which was completed in September 2019. We received a total of approximately 1.1 million shares for an average price of $176.61 per share. We have $200.5 million remaining available for repurchase under the May 2018 Repurchase Program.
Align Announcement Highlights
The following highlights recap Align’s recent announcements:
Corporate
- Align recently announced exciting co-marketing relationships with the San Francisco 49ers, Carolina Hurricanes, Super Bowl winning New England Patriots, and the 2019 NBA Champions the Toronto Raptors, making the Invisalign brand the official smile partner for each of these winning teams and creating new channels for Invisalign brand marketing. Working with great sports brands is a natural fit for Align. Partnering with teams who have adopted an omnichannel approach to brand marketing and engagement gives Align direct access to large, loyal fan bases and helps us reach individual consumers and whole families through a variety of existing fan platforms: in-stadium and through televised games, online, via social media, and in each team’s local community outreach programs. Align’s goal is the same for each: build awareness and demand for Invisalign treatment and connect interested and engaged consumers with Invisalign practices in their markets. It’s one more way that we can support doctors in this market of increased consumer choice.
- Align and Covestro AG announced that the Invisalign clear aligner system for straightening teeth, made with patented SmartTrack material, will be showcased at the K 2019 Plastics Trade Fair in Düsseldorf. The SmartTrack material solution was jointly developed by Align and Covestro.
- Align entered into and completed an ASR with Morgan Stanley & Co. LLC, to repurchase $200 million of Align's common stock as part of Align's $600 million stock repurchase program announced on May 23, 2018.
- Align appointed Ms. Anne Myong to the board of directors. Ms. Myong was previously Senior Vice President and Chief Financial Officer at Walmart Global eCommerce, where she accelerated the growth and digital transformation of their retail and e-commerce operations in the United States, China and Brazil.
- As part of Align’s $120 million annual commitment to raise consumer awareness of doctor directed Invisalign clear aligner treatment for better smiles, Align announced that it is a national sponsor for the premier healthy lifestyle brand Life Time.
Product
- Announced a global distribution agreement for the award-winning iTero Element family of intraoral scanners with Zimmer Biomet Dental, a global dental industry leader and provider of implant and restorative solutions and continuing education for dental professionals.
- Announced commercial availability of the iTero Element 2 scanner in China at the 2019 International Orthodontic Conference and the 18th Annual Meeting of the Chinese Orthodontic Society in Nanjing, China. The launch exemplifies Align’s continued innovation and investment to advance digital dentistry in China.
Q4 2019 Business Outlook
For the fourth quarter of 2019 (Q4’19), Align provides the following guidance:
- Net revenues in the range of $640 million to $650 million, up approximately 20% to 22% over the same period a year ago
- Invisalign case shipments in the range of 400 thousand to 407 thousand, up approximately 20% to 22% over the same period a year ago
- Operating margin in the range of 22.0% to 22.7%
- Diluted EPS in the range of $1.35 to $1.42
- In addition, we expect to repurchase at least $100 million of our stock in the open market in Q4'19
Align Web Cast and Conference Call
Align will host a conference call today, October 23, 2019 at 4:30 p.m. ET, 1:30 p.m. PT, to review its third quarter 2019 results, discuss future operating trends and the business outlook. The conference call will also be web cast live via the Internet. To access the webcast, go to the “Events & Presentations” section under Company Information on Align’s Investor Relations web site at http://investor.aligntech.com. To access the conference call, please dial 201-689-8261. An archived audio web cast will be available beginning approximately one hour after the call's conclusion and will remain available for approximately 12 months. Additionally, a telephonic replay of the call can be accessed by dialing 877-660-6853 with conference number 13694915 followed by #. For international callers, please dial 201-612-7415 and use the same conference number referenced above. The telephonic replay will be available through 5:30 p.m. ET on November 6, 2019.
About Align Technology, Inc.
Align Technology designs and manufactures the Invisalign® system, the most advanced clear aligner system in the world, and iTero® intraoral scanners and services. Align’s products help dental professionals achieve the clinical results they expect and deliver effective, cutting-edge dental options to their patients. Visit www.aligntech.com for more information.
For additional information about the Invisalign system or to find an Invisalign doctor in your area, please visit www.invisalign.com. For additional information about iTero digital scanning system, please visit www.itero.com.
Forward-Looking Statement
This news release, including the tables below, contains forward-looking statements, including statements regarding certain business metrics for the fourth quarter of 2019, including, but not limited to, anticipated net revenues, gross margin, operating expenses, operating profit, capital expenditures, depreciation and amortization, diluted earnings per share, tax rate, case shipments, and our expectations regarding stock repurchases during the quarter. Forward-looking statements contained in this news release and the tables below relating to expectations about future events or results are based upon information available to Align as of the date hereof. Readers are cautioned that these forward-looking statements are only predictions and are subject to risks, uncertainties and assumptions that are difficult to predict. As a result, actual results may differ materially and adversely from those expressed in any forward-looking statement. Factors that might cause such a difference include, but are not limited to, difficulties predicting customer and consumer purchasing behavior, including Align’s predictions related to a tougher consumer demand environment in China, especially for U.S. based products and services, Align’s expectations regarding the continued growth of our international markets, Align's ability to protect its intellectual property rights, continued compliance with regulatory requirements, competition from existing and new competitors, Align’s expectations regarding the sales growth of its intra-oral scanner sales in international markets, its belief that technology features and functionality of the iTero scanners will increase adoption of Invisalign and increase sales of Align’s intra-oral scanners, Align’s expectations regarding the financial and strategic benefits of establishing regional order acquisition, treatment planning and manufacturing facilities, the willingness and ability of our customers to maintain and/or increase product utilization in sufficient numbers, the possibility that the development and release of new products does not proceed in accordance with the anticipated timeline, the possibility that the market for the sale of these new products may not develop as expected, or that the expected benefits of new or existing business relationships will not be achieved as anticipated, Align’s expectation to incur additional costs related to the planned corporate structure reorganization, the risks relating to Align's ability to sustain or increase profitability or revenue growth in future periods while controlling expenses, the expected impact additional sales representatives will have on our sales, growth related risks, including excess or constrained capacity at our manufacturing and treat operations facilities and pressure on our internal systems and personnel, the security of customer and/or patient data is compromised for any reason, system integration and implementation issues, continued customer demand for our existing and new products, changes in consumer spending habits as a result of, among other things, prevailing economic conditions, levels of employment, salaries and wages and consumer confidence, the timing of case submissions from our doctors within a quarter as well as an increased manufacturing costs per case, acceptance of our products by consumers and dental professionals, foreign operational, political and other risks relating to Align's international manufacturing operations, Align's ability to develop and successfully introduce new products and product enhancements and the loss of key personnel. These and other risks are detailed from time to time in Align's periodic reports filed with the Securities and Exchange Commission, including, but not limited to, its Annual Report on Form 10-K for the year ended December 31, 2018, which was filed with the Securities and Exchange Commission (SEC) on February 28, 2019 and its latest Quarterly Report on Form 10-Q for the quarter ended June 30, 2019, which was filed with the SEC on August 1, 2019. Align undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
| Align Technology | Zeno Group: |
| Madelyn Homick | Sarah Johnson |
| (408) 470-1180 | (828) 551-4201 |
| [email protected] | [email protected] |
| ALIGN TECHNOLOGY, INC. | |||||||||||||||
| UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||||||||||
| (in thousands, except per share data) | |||||||||||||||
| Three Months Ended September 30, | Nine Month Ended September 30, | ||||||||||||||
| 2019 | 2018 | 2019 | 2018 | ||||||||||||
| Net revenues | $ | 607,341 | $ | 505,289 | $ | 1,757,009 | $ | 1,432,472 | |||||||
| Cost of net revenues | 169,787 | 133,508 | 485,070 | 367,701 | |||||||||||
| Gross profit | 437,554 | 371,781 | 1,271,939 | 1,064,771 | |||||||||||
| Operating expenses: | |||||||||||||||
| Selling, general and administrative | 277,514 | 213,873 | 792,572 | 625,585 | |||||||||||
| Research and development | 39,680 | 32,700 | 116,034 | 93,095 | |||||||||||
| Impairments and other (gains) charges | (6,792 | ) | - | 22,990 | - | ||||||||||
| Litigation settlement gain | - | - | (51,000 | ) | - | ||||||||||
| Total operating expenses | 310,402 | 246,573 | 880,596 | 718,680 | |||||||||||
| Income from operations | 127,152 | 125,208 | 391,343 | 346,091 | |||||||||||
| Interest income | 3,478 | 2,234 | 9,576 | 6,327 | |||||||||||
| Other income (expense), net | (2,211 | ) | (837 | ) | 5,935 | (7,759 | ) | ||||||||
| Net income before provision for income taxes and equity in losses of investee | 128,419 | 126,605 | 406,854 | 344,659 | |||||||||||
| Provision for income taxes | 25,895 | 24,601 | 77,812 | 35,206 | |||||||||||
| Equity in losses of investee, net of tax | - | 1,132 | 7,528 | 6,610 | |||||||||||
| Net income | $ | 102,524 | $ | 100,872 | $ | 321,514 | $ | 302,843 | |||||||
| Net income per share: | |||||||||||||||
| Basic | $ | 1.29 | $ | 1.26 | $ | 4.03 | $ | 3.78 | |||||||
| Diluted | $ | 1.28 | $ | 1.24 | $ | 4.00 | $ | 3.71 | |||||||
| Shares used in computing net income per share: | |||||||||||||||
| Basic | 79,332 | 80,111 | 79,709 | 80,122 | |||||||||||
| Diluted | 79,825 | 81,359 | 80,397 | 81,538 | |||||||||||
| ALIGN TECHNOLOGY, INC. | |||||
| UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS | |||||
| (in thousands) | |||||
| September 30, 2019 | December 31, 2018 | ||||
| ASSETS | |||||
| Current assets: | |||||
| Cash and cash equivalents | $ | 490,362 | $ | 636,899 | |
| Marketable securities, short-term | 292,011 | 98,460 | |||
| Accounts receivable, net | 531,816 | 439,009 | |||
| Inventories | 94,795 | 55,641 | |||
| Prepaid expenses and other current assets | 96,595 | 72,470 | |||
| Total current assets | 1,505,579 | 1,302,479 | |||
| Marketable securities, long-term | - | 9,112 | |||
| Property, plant and equipment, net | 606,581 | 521,329 | |||
| Operating lease right-of-use assets, net | 53,923 | - | |||
| Equity method investments | - | 45,913 | |||
| Goodwill and intangible assets, net | 77,012 | 81,949 | |||
| Deferred tax assets | 63,150 | 64,689 | |||
| Other assets | 44,135 | 26,987 | |||
| Total assets | $ | 2,350,380 | $ | 2,052,458 | |
| LIABILITIES AND STOCKHOLDERS' EQUITY | |||||
| Current liabilities: | |||||
| Accounts payable | $ | 63,300 | $ | 64,256 | |
| Accrued liabilities | 286,132 | 234,679 | |||
| Deferred revenues | 520,712 | 393,138 | |||
| Total current liabilities | 870,144 | 692,073 | |||
| Income tax payable | 101,914 | 78,008 | |||
| Operating lease liabilities | 43,365 | - | |||
| Other long-term liabilities | 29,408 | 29,486 | |||
| Total liabilities | 1,044,831 | 799,567 | |||
| Total stockholders' equity | 1,305,549 | 1,252,891 | |||
| Total liabilities and stockholders' equity | $ | 2,350,380 | $ | 2,052,458 | |
| ALIGN TECHNOLOGY, INC. | |||||||
| UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | |||||||
| (in thousands) | |||||||
| Nine Months Ended September 30, | |||||||
| 2019 | 2018 | ||||||
| CASH FLOWS FROM OPERATING ACTIVITIES | |||||||
| Net cash provided by operating activities | $ | 529,093 | $ | 313,386 | |||
| CASH FLOWS FROM INVESTING ACTIVITIES | |||||||
| Net cash used in investing activities | (290,333 | ) | (24,021 | ) | |||
| CASH FLOWS FROM FINANCING ACTIVITIES | |||||||
| Net cash used in financing activities | (383,163 | ) | (315,151 | ) | |||
| Effect of foreign exchange rate changes on cash, cash equivalents, and restricted cash | (2,098 | ) | (2,890 | ) | |||
| Net decrease in cash, cash equivalents, and restricted cash | (146,501 | ) | (28,676 | ) | |||
| Cash, cash equivalents, and restricted cash at beginning of the period | 637,566 | 450,125 | |||||
| Cash, cash equivalents, and restricted cash at end of the period | $ | 491,065 | $ | 421,449 | |||
| ALIGN TECHNOLOGY, INC. | |||||||||||||||||||||||||||||||
| INVISALIGN BUSINESS METRICS* | |||||||||||||||||||||||||||||||
| Q1 | Q2 | Q3 | Q4 | Fiscal | Q1 | Q2 | Q3 | ||||||||||||||||||||||||
| 2018 | 2018 | 2018 | 2018 | 2018 | 2019 | 2019 | 2019 | ||||||||||||||||||||||||
| Invisalign Average Selling Price (ASP): | |||||||||||||||||||||||||||||||
| Worldwide ASP | $ | 1,310 | $ | 1,315 | $ | 1,230 | $ | 1,235 | $ | 1,270 | $ | 1,245 | $ | 1,230 | $ | 1,260 | |||||||||||||||
| International ASP | $ | 1,435 | $ | 1,425 | $ | 1,340 | $ | 1,295 | $ | 1,370 | $ | 1,330 | $ | 1,305 | $ | 1,330 | |||||||||||||||
| Invisalign Cases Shipped by Geography: | |||||||||||||||||||||||||||||||
| Americas | 166,665 | 181,425 | 190,615 | 189,410 | 728,115 | 202,935 | 211,360 | 215,355 | |||||||||||||||||||||||
| International | 105,570 | 121,260 | 128,730 | 144,390 | 499,950 | 146,260 | 165,785 | 170,005 | |||||||||||||||||||||||
| Total Cases Shipped | 272,235 | 302,685 | 319,345 | 333,800 | 1,228,065 | 349,195 | 377,145 | 385,360 | |||||||||||||||||||||||
| YoY % growth | 30.8 | % | 30.5 | % | 35.3 | % | 30.9 | % | 31.9 | % | 28.3 | % | 24.6 | % | 20.7 | % | |||||||||||||||
| QoQ % growth | 6.7 | % | 11.2 | % | 5.5 | % | 4.5 | % | 4.6 | % | 8.0 | % | 2.2 | % | |||||||||||||||||
| Number of Invisalign Doctors Cases Were Shipped To: | |||||||||||||||||||||||||||||||
| Americas | 27,105 | 28,280 | 28,890 | 29,215 | 42,000 | 30,200 | 31,445 | 31,975 | |||||||||||||||||||||||
| International | 19,700 | 21,805 | 23,270 | 25,475 | 36,040 | 26,510 | 28,970 | 30,980 | |||||||||||||||||||||||
| Total Doctors Cases Shipped To | 46,805 | 50,085 | 52,160 | 54,690 | 78,040 | 56,710 | 60,415 | 62,955 | |||||||||||||||||||||||
| Invisalign Doctor Utilization Rates**: | |||||||||||||||||||||||||||||||
| North America | 6.3 | 6.6 | 6.9 | 6.7 | 18.2 | 7.0 | 7.0 | 7.0 | |||||||||||||||||||||||
| North American Orthodontists | 15.3 | 16.4 | 17.4 | 16.5 | 56.7 | 18.3 | 18.9 | 19.1 | |||||||||||||||||||||||
| North American GP Dentists | 3.4 | 3.6 | 3.5 | 3.6 | 9.1 | 3.6 | 3.6 | 3.5 | |||||||||||||||||||||||
| International | 5.4 | 5.6 | 5.5 | 5.7 | 13.9 | 5.5 | 5.7 | 5.5 | |||||||||||||||||||||||
| Total Utilization Rates | 5.8 | 6.0 | 6.1 | 6.1 | 15.7 | 6.2 | 6.2 | 6.1 | |||||||||||||||||||||||
| Number of Invisalign Doctors Trained: | |||||||||||||||||||||||||||||||
| Americas | 1,630 | 1,880 | 2,085 | 2,290 | 7,885 | 1,840 | 3,070 | 2,760 | |||||||||||||||||||||||
| International | 2,645 | 3,300 | 2,845 | 2,980 | 11,770 | 2,410 | 3,520 | 3,135 | |||||||||||||||||||||||
| Total Doctors Trained Worldwide | 4,275 | 5,180 | 4,930 | 5,270 | 19,655 | 4,250 | 6,590 | 5,895 | |||||||||||||||||||||||
| Total to Date Worldwide | 136,575 | 141,755 | 146,685 | 151,955 | 151,955 | 156,205 | 162,795 | 168,690 | |||||||||||||||||||||||
| * Invisalign business metrics exclude SmileDirectClub aligners. | |||||||||||||||||||||||||||||||
| ** # of cases shipped / # of doctors to whom cases were shipped. LATAM utilization rate is not separately disclosed, but included in the total utilization rates. | |||||||||||||||||||||||||||||||
| ALIGN TECHNOLOGY, INC. | |||||||||||||||||||||||||||||||
| STOCK-BASED COMPENSATION | |||||||||||||||||||||||||||||||
| (in thousands) | |||||||||||||||||||||||||||||||
| Q1 | Q2 | Q3 | Q4 | Fiscal | Q1 | Q2 | Q3 | ||||||||||||||||||||||||
| 2018 | 2018 | 2018 | 2018 | 2018 | 2019 | 2019 | 2019 | ||||||||||||||||||||||||
| Stock-based Compensation (SBC) | |||||||||||||||||||||||||||||||
| SBC included in Gross Profit | $ | 881 | $ | 900 | $ | 966 | $ | 948 | $ | 3,695 | $ | 1,112 | $ | 1,278 | $ | 1,354 | |||||||||||||||
| SBC included in Operating Expenses | 14,949 | 15,990 | 18,232 | 17,897 | 67,068 | 19,932 | 21,189 | 22,822 | |||||||||||||||||||||||
| Total SBC | $ | 15,830 | $ | 16,890 | $ | 19,198 | $ | 18,845 | $ | 70,763 | $ | 21,044 | $ | 22,467 | $ | 24,176 | |||||||||||||||
ALIGN TECHNOLOGY, INC.
BUSINESS OUTLOOK SUMMARY
(unaudited)
The outlook figures provided below and elsewhere in this press release are approximate in nature since Align’s business outlook is difficult to predict. Align’s future performance involves numerous risks and uncertainties and the company’s results could differ materially from the outlook provided. Some of the factors that could affect Align’s future financial performance and business outlook are set forth under “Forward Looking Information” above in this press release.
| Financial Outlook | |||
| (in millions, except per share amounts and percentages) | |||
| Q4'19 Guidance | |||
| GAAP | |||
| Net Revenues | $640 - $650 | ||
| Gross Margin | 71.7% - 72.4% | ||
| Operating Expenses | $318 - $323 | ||
| Operating Margin | 22.0% - 22.7% | ||
| Net Income per Diluted Share | $1.35 - $1.42 | ||
| Business Metrics: | Q4'19 | ||
| Case Shipments | 400K - 407K | ||
| Capital Expenditure | $30M-$35M | ||
| Depreciation & Amortization | $22M-$24M | ||
| Diluted Shares Outstanding | 79.4M | (1) | |
| Stock Based Compensation Expense | $24.0M | ||
| Effective Tax Rate | ~24% | (2) | |
| (1) | Excludes any stock repurchases during the quarter |
| (2) | Includes excess tax benefits related to share-based compensation expense pursuant to ASU 2016-09 |